Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102 + Pembrolizumab +/- Chemotherapy in Metastatic NSCLC
NCT03562871Phase 2Completed
- Sponsor
- IO Biotech
- Start
- Aug 2018
- Primary completion
- Feb 2021
- Modality
- Prophylactic Vaccines, Peptide-based Cancer Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of io102 in non-small cell lung cancer (NSCLC), sponsored by IO Biotech. Started Aug 2018; status: completed.
02
Drugs
io102
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03562871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562871.